Diagnostic methods for Helicobacter pylori detection and eradication

British Journal of Clinical Pharmacology

Volumn 56, Issue 3, 2003, Pages 273-283

  Goddard, A F ^a   Logan, R P H ^b,c  

^a DERBY CITY GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Drug development; Drug treatment; Helicobacter pylori

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIULCER AGENT; BACTERIAL ANTIGEN; BISMUTH; CAGA PROTEIN; CARBON 13; CLARITHROMYCIN; HELICOBACTER PYLORI VACCINE; METRONIDAZOLE; NAP PROTEIN; NITROIMIDAZOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; TINIDAZOLE; UNCLASSIFIED DRUG; VACUOLATING TOXIN;

ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; BACTERIUM DETECTION; DIAGNOSTIC TEST; DIARRHEA; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DYSPEPSIA; ERADICATION THERAPY; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER PYLORI; HUMAN; INFECTION PREVENTION; MINIMUM INHIBITORY CONCENTRATION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PATIENT COMPLIANCE; PEPTIC ULCER; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; STOMACH CANCER; STOMACH MUCUS; TASTE DISORDER; UREA BREATH TEST; VACCINATION; VALIDATION PROCESS;

ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; BACTERIOLOGICAL TECHNIQUES; CLINICAL TRIALS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PATIENT COMPLIANCE; RECURRENCE; RISK FACTORS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 0041317452     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01941.x     Document Type: Review

References (109)

1. Marshall BJ, Warren JR, Goodwin CS. Duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1989; i: 846.
2. Jones DM, Lessels AM, Eldridge J. Campylobacter like organisms in the gastric mucosa: Culture, histological and serological studies. J Clin Pathol 1984; 37: 1002-1006.
3. Logan RPH, Walker MM. Epidemiology and diagnosis of Helicobacter pylori infection. Br Med J 2001; 323: 920-922.
4. Whitaker CJ, Dubiel AJ. Gaplin. Social and geographical risk factors in Helicobacter pylori infection. Epidemiol Infect 1993; 111: 63.
5. Neale KR, Logan RPH. The epidemiology and transmission of Helicobacter pylori infection in children. Aliment Pharmacol 1995; 9(Suppl 2): 77-84.
6. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-69.
7. International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. Lyon: IARC, 1994; 61: 177-241.
8. Blaser MJ. Hypothesis on the pathogenesis and natural history of H. pylori inflammation. Gastroenterol 1992; 102: 720-727.
9. Baron JH, Logan RPH. Infection by Helicobacter pylori is the major cause of duodenal ulcer. Proc R Coll Physicians Edin 1994; 24: 21-36.
10. Crabtree JE, Wyatt JI, Tredosiewicz LK, et al. Interleukin-8 expression in Helicobacter pylori infected, normal and neoplastic gastroduodenal mucosa. J Clin Pathol 1994; 47: 61-66.
11. Guillemin K, Salama NR, Tompkins LS, Falkow S. Cag pathogenicity island-specific responses of gastric epithelial cells to Helicobacter pylori infection. Proc Natl Acad Sci USA 2002; 99: 15136-15141.
12. Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 2003; 300: 1430-1434.
13. Sipponen P, Kekki M, Siurala M. The Sydney System: Epidemiology and natural history of chronic gastritis. J Gastroenterol Hepatol 1991; 6: 244-251.
14. El-Omar EM, Carrington M, Chow WH, et al. The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature 2001; 412: 99.
15. El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of non-cardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-1201.
16. Marshall BJ, Goodwin CS, Warren JR, et al. A prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; ii: 1437-1441.
17. Coghlan JG, Humphries H, Dooley C, et al. Campylobacter pylori and recurrence of duodenal ulcers - a 12-month follow-up study. Lancet 1987; ii: 1109-1111.
18. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer with eradication of Helicobacter pylori. Lancet 1990; 335: 1233-1235.
19. Axon AR. Duodenal ulcer: the villain unmasked? Br Med J 1991; 302: 919-921.
20. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med, 1991; 324: 1048.
21. Graham DY. NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med, 2002; 347: 2162-2164.
22. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis Lancet 2002; 359: 14-22.
23. Hawkey CJ, Wilson I, Naesdal J, Langstrom G, Swannell AJ, Yeomans ND. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut 2002; 51: 344-350.
24. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002; 16: 497-506.
25. Kemmer TP, Dominguez-Munoz JE, Klingel H, Zemmler T, Kuhn K, Malfertheiner P. The association between non-ulcer dyspepsia and Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1994; 6: 571-577.
26. Veldhuerzen van Zanten S, Malatjalian D, Tanton R, et al. The effect of eradication of Helicobacter pylori (Hp) on symptoms of no-ulcer dyspepsia (NUD): a randomised double blind placebo controlled trial. Gastroenterology 1995; 108: A250.
27. Moayyedi P, Deeks J, Forman D. Helicobacter pylori eradication therapy for nonulcer dyspepsia. Ann Intern Med 2002; 136: 555-556.
28. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003; 1: CD002096.
29. Vaira D, Miglioli M, Mule P, et al. The prevalence of peptic ulcer in Helicobacter pylori positive blood donors. Gut 1994; 35: 309-312.
30. Wotherspoon AC. A critical review of the effect of Helicobacter pylori eradication on gastric MALT lymphoma. Curr Gastroenterol Report 2000; 6: 494-498.
31. Isaacson PG, Diss TC, Wotherspoon AC, Barbazza R, De Boni M, Doglioni C. Long-term follow-up of gastric MALT lymphoma treated by eradication of H. pylori with antibodies. Gastroenterology 1999; 117: 750-751.
32. Sakaki N, Momma K, Egawa N, Yamada Y, Kan T, Ishiwata J. Influence of Helicobacter pylori infection on the progress of gastric mucosal atrophy and the occurrence of gastric cancer. Am J Gastroenterol 1994; 89: A462.
33. Lamouliatre H, Carles B, Cayla R, Zerbib F, de Mascarel A, Megraud F. Helicobacter pylori eradication can normalise gastric mucosa. Am J Gastroenterol 1994; 89: A295.
34. Xia HH, Wong BC, Lam SK. Chemoprevention of gastric cancer: current status. Chin Med J (Engl) 2003; 116: 5-10.
35. Correa P. Helicobacter pylori infection and gastric cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 238S-41S.
36. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 2000; 92: 1881-1888.
37. Rauws EA, Langenberg W, Houthoff HJ, Zanen HC, Tytgat GNJ. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988; 94: 33-40.
38. Heatley RV. Review article, the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1992; 6: 291-303.
39. Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-1727.
40. Penston JG. Review article: Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994; 8: 369-389.
41. Tytgat GNJ. Review article, treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359-368.
42. Glupczynski Y, Burette A. Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol 1990; 85: 1545-1551.
43. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ, Klein PD. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-496.
44. Rautelin H, Seppala K, Renkonen OV, Vainio U, Kosunen TU. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother 1992; 36: 163-166.
45. Cutler AF, Schubert TT. Parent factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993; 88: 505-509.
46. Bazzoli F, Zagari RM, Fossi S, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 773-777.
47. Labenz J, Stolte M, Ruhl GH, et al. One week low dose triple therapy for cure of Helicobacter pylori infection. Eur J Gastroenterol 1995; 7: 9-11.
48. Yousfi MM, El-Zimaity HMT, Al-Assi MT, Cole RA, Genta RM, Graham DY. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 209-212.
49. Adamek RJ, Szymanski C, Pfaffenbach B, Opferkuch W, Ricken D, Wegener M. Short term triple treatment of Helicobacter pylori infection with pantoprazole, clarithromycin and metronidazole. Dtsch Med Wschr 1995; 120: 358-360.
50. Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using 1-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter 1996; 1: 138-143.
51. Calabrese C, Di Febo G, Areni A, et al. Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 1613-1617.
52. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-253.
53. Bazzoli F, Zagari RM, Pozzato P, et al. Low-dose lansoprazole and clarithromycin plus metronidazole vs full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16: 153-158.
54. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180.
55. Huang JQ, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther 1999; 13: 719-729.
56. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 1319-1328.
57. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrobial Agents Chemother 1991; 35: 490-496.
58. Figura N, Armellini D, Bugnoli M, Bayeli PF, Gennari C, Crabtree JE. Activity of omeprazole on H. pylori and relation to toxicity of strains. J Clin Pathol 1994; 47: 440-442.
59. 14C-urea breath rest in ferrets colonised with H. mustelae. Gut 1993; 34: 181-186.
60. Moayyedi P, Axon ATR. Patient factors that predict failure of omeprazole, clarithromycin and tinidazole (OCT) to eradicate Helicobacter pylori (H. pylori). Gut 1995; 37(Suppl 1): A46.
61. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology, 1998; 115: 1272-1277.
62. Toracchio S, Cellini L, Di Camli E, et al. Role of antibiotic susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 639-643.
63. Glupczynski Y, Megraud F, Lopez-Brea M, et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Microbiol Infect Dis 2001; 20: 820-823.
64. Van der Wouden EJ, Thijs JC, van Zwet AA, et al. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999; 94: 1751-1759.
65. Goddard AF. Factors influencing antibiotic transfer across gastric mucosa. Aliment Pharmacol Ther 1998; 12: 1175-1184.
66. Back S, Carling L, Ekström P, et al. Eradication of Helicobacter pylori with either phenoxymethylpenicillin, benzylpenicillin or amoxycillin in combination with omeprazole: a Swedish multi-centre study. Gastroenterology 1995; 108: A532 (Abstract).
67. Atherton JC, Cockayne A, Balsitis M, et al. Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxycillin and cimetidine. Gut 1995; 36: 670-674.
68. Cooreman MP, Krausgrill P, Hengels KJ. Local gastric and serum amoxycillin concentrations after different oral application forms. Antimicrob Agents Chemother 1995; 39: 2084-2087.
69. Atherton JC, Washington N, Bracewell MA, et al. Scintigraphic assessment of the intragastric distribution and gastric emptying of an encapsulated drug: the effect of feeding and of a proton pump inhibitor. Aliment Pharmacol Ther 1994; 8: 489-494.
70. Goddard AF, Jessa MJ, Barrett DA, et al. Effect of omeprazole on the distribution of metronidazole, clarithromycin and amoxycillin in human gastric juice. Gastroenterology 1996; 111: 358-367.
71. Grübel P, Cave D. Factors affecting the penetration of clarithromycin through gastric mucus. Aliment Pharmacol Ther 1998; 12: 569-576.
72. Goddard AF, Spiller RC. The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. Aliment Pharmacol Ther 1996; 10: 105-109.
73. Lozniewski A, de Korwin JD, Muhale F, Jehl F. Gastric diffusion of antibiotics used against H. pylori. Int J Antimicrob Agent 1998; 9: 181-193.
74. Goddard AF, Erah PO, Barrett DA, et al. The effect of protein binding and lipophilicity of penicillins on their in vitro flux across gastric mucosa. J Antimicrob Chemother 1998; 41: 231-236.
75. Calafatti SA, dos Santos A, da Silva CMF, et al. Transfer of metronidazole to gastric juice: impact of Helicoabacter pylori infection and omeprazole. Scand J Gastroenterol 2000; 35: 699-704.
76. Pedrazzoli J, Calafatti SA, Ortiz RAM, et al. Transfer of clarithromycin to gastric juice is enhanced by omeprazole in Helicobacter pylori-infected individuals. Scand J Gastroenterol 2001; 36: 1248-1253.
77. Gustavson LE, Kaiser JF, Edmonds AL, et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39: 2078-2083.
78. Goddard AF, Erah PO, Atherton JC, et al. Effect of H. pylori, aspirin and anoxia on antibiotic permeability in the rat stomach. Gastroenterology 1997; 112: A128 (Abstract)
79. Sherwood PV, Wibawa JID, Barrett DA, et al. Effect of Helicobacter gastritis on antibiotic secretion in man. Gut 2001; 48: A31 (Abstract).
80. Sherwood PV, Wibawa JID, Jordan N, et al. Gastric secretion of amoxycillin and metronidazole is increased by pronase a luminal mucolytic. Gut 2001; 48: A15 (Abstract).
81. Erah PO, Goddard AF, Barrett DA, et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39: 5-12.
82. Westblum TU, Duriex DE. Antibiotic concentrations in the gastric mucosa: The guinea pig model. In Helicobacter pylori 1990, eds Menge, H, et al. Berlin: Springer-Verlag, 1991; 157-161.
83. Endo H, Yoshida H, Ohmi N, et al. Localisation of (14C) clarithromycin in rat gastric tissue when administered with lansoprazole and amoxicillin. J Antimicrob Chemother 2002; 50: 285-288.
84. 14C) amoxycillin into rat gastric mucosa. J Antimicrob Chemother 2001; 47: 405-410.
85. 13C-Urea Breath Test for the detection of Helicobacter pylori. Eur J Gastroenterol Hepatol 1991; 3: 915-921.
86. 13C-UBT for the detection of Helicobacter pylori. In Helicobacter pylori and gastroduodenal disease, 2nd edn, eds Rathbone BJ, Heatley RV. London: Blackwell, 1992; 88-107.
87. Logan RPH. Breath tests to detect Helicobacter pylori. In Helicobacter pylori: Biology and Clinical Practice, eds Goodwin S, Worsley B. Florida, CRC Press Inc., 1993; 307-327.
88. 13C-urea breath test. Am J Gastroenterol 1993; 88: 1865-1868.
89. 13C-urea breath test to quantify H. pylori colonisation of gastric mucosa and association with severity of inflammation. Gastroenterology 1994; 105: A180.
90. 13C-urea breath test. Gut 1991; 32: A565.
91. 13C-urea breath test. Aliment Pharmacol Ther 1992; 6: 97-102.
92. Logan RPH, Walker MM, Misiewicz JJ, Gummett PA, Baron JH. Changes in the intragastric distribution of H. pylori during treatment with omeprazole. Gut 1995; 36: 12-16.
93. Logan RPH, Gummett PA, Misiewicz JJ, Walker MM, Jameson J, Poison RJ, Karim QN, Duggan AE. The efficacy of ranitidine bismuth citrate (GR122311X) in the treatment of Helicobacter pylori infection. Gastroenterology 1992; 102: A114.
94. Logan RPH, Hurlimann S, Gummett PA, Walker MM, Karim QN, Baron JH, Misiewicz JJ. How quickly does Helicobacter pylori (H. pylori) recur after treatment. Gut 1992; 33(Suppl 1): S3 (Abstract).
95. Logan RPH, Polson RJ, Baron JH, Misiewicz JJ. Follow-up after anti-Helicobacter pylori treatment. Lancet 1991; 337: 562-563.
96. Logan RPH, Gummett PA, Polson RJ, Baron JH, Misiewicz JJ. What length of treatment with tripotassium dicitratobismuthate (TDB) for Helicobacter pylori? Gut 1990; 31: A1178.
97. Axon A, Deltentre M, Eriksson S, et al. Guidelines for clinical trials in Helicobacter pylori infection. Gut 1997; 41(Suppl 2): 1-23.
98. Megraud F, Burette A, Glupczynski Y, et al. Comparison of tests for the assessment of Helicobacter pylori eradication: results of a multicentre study using centralised facility testing. Eur J Gastroenterol Hepatol 2000; 12: 629-633.
99. 13C-urea breath tests (UBT) in assessment of eradication? Gut 1996; 39(Suppl 2): A118.
100. Newell DG, Stacey AR. The serology of Helicobacter pylori. In Helicobacter pylori and gastroduodenal disease, 2nd edn, eds Rathbone BJ, Headey RV. London: Blackwell, 1992; 74-82.
101. Hirschl AM, Rathbone BJ, Wyatt JI, Berger J, Rotter ML. Comparison of ELISA antigen preparations alone or in combination for serodiagnosing Helicobacter pylori infections. J Clin Pathol 1990; 43: 511-513.
102. 13C-urea breath test for detecting Helicobacter pylori infection and monitoring eradication treatment: prospective clinical evaluation. Br Med J 2000; 320: 148.
103. Gisbert JP, Pajares JM. Diagnosis of Helicobacter pylori infection stool antigen determination: a systematic review. Am J Gastroenterol 2001; 96: 2829-2838.
104. Morris A, Ali MR, Brown P, Lane M, Patton K. Campylobacter pylori infection in biopsy specimens of gastric antrum: laboratory diagnosis and estimation of sampling error. J Clin Pathol 1989; 42: 727-732.
105. McMullen L, Walker MM, Bain LA, Karim QN, Baron JH. Histological identification of Campylobacter using Gimenez technique in gastric antral mucosa. J Clin Pathol 1987; 40: 464-465.
106. Czinn SJ, Nedrun JG. Oral immunisation against H. pylori. Infect Immun 1991; 59: 2359-2363.
107. Doidge C, Lee A, Buck F, Hazell S, Manne U, Gust I. Therapeutic immunisation against Helicobacter infection. Am J Gastroenterol 1994; 89: A339.
108. Del Giudice G, Covacci A, Telford JL, Montecucco C, Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 2001; 19: 523-563.
109. Ruggiero P, Peppoloni S, Berti D, Rappuoli R, Giudice GD. New strategies for the prevention and treatment of Helicobacter pylori infection. Expert Opin Invest Drugs 2002; 11: 1127-1138.